Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Hematologists who Treat Lymphoma(?)

Council Members in this Study Group: 63

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

What is a GLG Leader?
Eric Jacobsen, MD
Instructor in Medicine
Dana-Farber Cancer Institute, Harvard Medical School

Eric Jacobsen, MD, is a Medical Oncologist and Hematologist in the Hematology/Oncology Department at Dana Farber Cancer Institute in Boston, Massachusetts. His clinical focus is on lymphoma and is very involved in Phase II/III clinical trials for new compounds as well as stem cell transplantation.

Kenneth Algazy, MD, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CCKenneth Algazy, MD
Clinical Professor of Medicine
University of Pennsylvania School of Medicine - CC

Dr. Kenneth Algazy, MD, is a Clinical Professor of Medicine at University of Pennsylvania School of Medicine. He is also a Section Chief in the Division of Hematology and Oncology at Philadelphia VA Medical Center. Dr. Algazy is involved in clinical trials in lung cancer, and interested in demographics...

Donald Tsai, MD PhD
Assistant Professor of Medicine
University of Pennsylvania Cancer Center

Donald Tsai, MD, PhD, is an Assistant Professor of Medicine at the University of Pennsylvania Cancer Center. Dr. Tsai specializes in the treatment of hematological malignancies such as leukemia, multiple myeloma, lymphoma, Hodgkin's disease, myelodysplastic syndromes (MDS), and bone marrow transplantation....

GLG NewsSMAnalyses by this Study Group's Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Is Alimta (Lilly) the answer? (What is the question?) | 07-21-2008
Author: Kenneth Algazy, MD, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC

Individualizing chemotherapy depending on histology (adenocarcinomas) shows that Alimta/CisPlatin appears to be more convenient and less toxic than its stablemate Gemzar.

As if Rituxan (Genentech/Biogen) needed another market? | 07-21-2008
Author: Kenneth Algazy, MD, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC

For patients with antibodies that may make renal transplants problematic, Rituxan may make them possible!

Notice the US is not part of the discussion? | 07-14-2008
Analysis of: Glaxo Seeks Guidance From Health Systems | online.wsj.com
Author: Kenneth Algazy, MD, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC

GSK is discussing drug development with European countries and not the US. Implications???

Medicare fee cuts: Saved by someone who may appreciate the significance........ | 07-10-2008
Analysis of: Bill to Block Medicare-Fee Cuts | online.wsj.com
Author: Kenneth Algazy, MD, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC

Medicare will not cut physicians fees but will cut payments in HMO driven Medicare "advantage" plans. This means that the republicans will be unable to "feather the nest" of their insurer friends!

Further evidence that government intervention is around the corner | 07-09-2008
Analysis of: Pricey Drugs Put Squeeze on Doctors | online.wsj.com
Author: Kenneth Algazy, MD, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC

Chemotherapy drugs are so costly that not only are the patients unable to pay co-pays, but oncologists are laying out hundreds of thousands of dollars with only a promise they will be reimbursed.

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Non-Academic Community Hospital or Clinic
  • Academic Institution*

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Division Head
  • Physician - Director
  • Partner
  • Assistant Professor

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics